1. Home
  2. TDF vs PLYX Comparison

TDF vs PLYX Comparison

Compare TDF & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

HOLD

Current Price

$11.21

Market Cap

280.0M

Sector

Finance

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$4.61

Market Cap

271.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TDF
PLYX
Founded
1994
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.0M
271.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TDF
PLYX
Price
$11.21
$4.61
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
49.1K
117.5K
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.09
$2.20
52 Week High
$12.20
$9.18

Technical Indicators

Market Signals
Indicator
TDF
PLYX
Relative Strength Index (RSI) 52.16 40.50
Support Level $11.01 $2.58
Resistance Level $11.41 $7.29
Average True Range (ATR) 0.25 0.58
MACD -0.01 -0.13
Stochastic Oscillator 33.75 1.25

Price Performance

Historical Comparison
TDF
PLYX

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: